Your browser doesn't support javascript.
loading
What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?
Henrikson, Nora B; Wagner, Jennifer K; Hampel, Heather; DeVore, Christopher; Shridhar, Nirupama; Williams, Janet L; Donohue, Katherine E; Kullo, Iftikhar; Prince, Anya E R.
Affiliation
  • Henrikson NB; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Wagner JK; Geisinger Health System, Danville, PA, USA.
  • Hampel H; Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA.
  • DeVore C; Asian Pacific American Institute for Congressional Studies, Washington DC, USA.
  • Shridhar N; Washington State Department of Health, Tumwater, WA USA.
  • Williams JL; Geisinger Health System, Danville, PA, USA.
  • Donohue KE; The Icahn School of Medicine at Mount Sinai, New York, NY.
  • Kullo I; Mayo Clinic, Rochester, MN, USA.
  • Prince AER; University of Iowa, College of Law, Iowa City, IA, USA.
J Law Biosci ; 7(1): lsaa071, 2020.
Article in En | MEDLINE | ID: mdl-34221429
ABSTRACT

BACKGROUND:

It is unclear how the Health Insurance Portability and Accountability Act (HIPAA) should be interpreted in the context of sharing of genomic information between family members.

METHODS:

The authors analyzed the HIPAA Privacy Rule, reviewed the literature and constructed a clinical scenario to inform how HIPAA can be interpreted for multiple forms of patient- and provider-mediated genetic risk notification.

RESULTS:

Under HIPAA, healthcare providers can lawfully notify relatives to recommend genetic risk assessment using multiple approaches, including supporting the patient telling their own relatives, contacting relatives directly with the patient's authorization, or contacting a relative's provider directly.

CONCLUSIONS:

Multiple forms of patient- or provider-mediated contact of relatives are already legally permissible under HIPAA, are consistent with ethical obligations of care to patients and their families, and could result in improved population health through identification of clinically actionable disease risk. Unanswered questions remain about implementation and impacts of provider-mediated programs.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Guideline / Risk_factors_studies / Screening_studies Aspects: Ethics Language: En Journal: J Law Biosci Year: 2020 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Guideline / Risk_factors_studies / Screening_studies Aspects: Ethics Language: En Journal: J Law Biosci Year: 2020 Document type: Article Affiliation country: